Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy

Objective: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic cerebral palsy, but its added value preceding comprehensive rehabilitation for motor impairments, gait, and goal attainment has not been studied. Design: A comparative multi-centre trial, i...

Full description

Bibliographic Details
Main Authors: Fabienne Schasfoort, Robert Pangalila, Emiel M. Sneekes, Coriene Catsman, Jules Becher, Herwin Horemans, Henk J. Stam, Annet J. Dallmeijer, Johannes B.J Bussmann
Format: Article
Language:English
Published: Foundation for Rehabilitation Information 2018-07-01
Series:Journal of Rehabilitation Medicine
Subjects:
Online Access: https://www.medicaljournals.se/jrm/content/html/10.2340/16501977-2369
id doaj-36e7da2cf31144a186e6964fd276de54
record_format Article
spelling doaj-36e7da2cf31144a186e6964fd276de542020-11-25T00:08:42ZengFoundation for Rehabilitation InformationJournal of Rehabilitation Medicine1650-19771651-20812018-07-0150873274210.2340/16501977-23692447Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsyFabienne Schasfoort0Robert PangalilaEmiel M. SneekesCoriene CatsmanJules BecherHerwin HoremansHenk J. StamAnnet J. DallmeijerJohannes B.J Bussmann Rehabilitation Medicine, Erasmus MC, 3000 CA Rotterdam, The Netherlands. f.schasfoort@erasmusmc.nl. Objective: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic cerebral palsy, but its added value preceding comprehensive rehabilitation for motor impairments, gait, and goal attainment has not been studied. Design: A comparative multi-centre trial, in which two groups underwent comprehensive rehabilitation (i.e. high-intensive functional physiotherapy, and indicated casting/orthoses). One group received intramuscular BoNT-A prior to rehabilitation, and the other group did not receive BoNT-A. Subjects/patients: Children with spastic cerebral palsy, Gross Motor Function Classification System (GMFCS) levels I–III, age range 4–12 years, indicated for BoNT-A treatment regarding mobility problems. Methods: Sixty-five children participated (37 boys), mean age 7.3 years (standard deviation (SD) 2.3, range 4–12 years), equally distributed across GMFCS levels. Forty-one children received BoNT-A+ comprehensive rehabilitation and 24 received comprehensive rehabilitation only. Functional leg muscle strength, passive range of motion, angle of catch, cerebral palsy-related pain, walking speed, kinematic gait parameters, goal attainment, and proxy-reported general functioning were assessed at baseline, primary end-point (12 weeks) and 24-week follow-up. Statistical analyses were performed with linear mixed models. Results: At the primary end-point there were no statistically significant differences in treatment effects between the groups, except for the angle-of-catch of the rectus femoris, which was in favour of comprehensive rehabilitation without BoNT-A (12° difference, 95% confidence interval (95% CI) 2:23, p = 0.025). Results at follow-up were similar. Conclusion: At the group level, treating with BoNT-A prior to comprehensive rehabilitation did not add to the clinical effectiveness of rehabilitation. Thus, BoNT-A prescription and use should be critically reconsidered in this cerebral palsy age- and GMFCS-subgroup. https://www.medicaljournals.se/jrm/content/html/10.2340/16501977-2369 spasticcerebralpalsybotulinumtoxinfunctionalphysiotherapycastingorthosesimpairmentsgoalattainmentpaediatricrehabilitation
collection DOAJ
language English
format Article
sources DOAJ
author Fabienne Schasfoort
Robert Pangalila
Emiel M. Sneekes
Coriene Catsman
Jules Becher
Herwin Horemans
Henk J. Stam
Annet J. Dallmeijer
Johannes B.J Bussmann
spellingShingle Fabienne Schasfoort
Robert Pangalila
Emiel M. Sneekes
Coriene Catsman
Jules Becher
Herwin Horemans
Henk J. Stam
Annet J. Dallmeijer
Johannes B.J Bussmann
Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy
Journal of Rehabilitation Medicine
spasticcerebralpalsy
botulinumtoxin
functionalphysiotherapy
casting
orthoses
impairments
goalattainment
paediatricrehabilitation
author_facet Fabienne Schasfoort
Robert Pangalila
Emiel M. Sneekes
Coriene Catsman
Jules Becher
Herwin Horemans
Henk J. Stam
Annet J. Dallmeijer
Johannes B.J Bussmann
author_sort Fabienne Schasfoort
title Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy
title_short Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy
title_full Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy
title_fullStr Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy
title_full_unstemmed Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy
title_sort intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy
publisher Foundation for Rehabilitation Information
series Journal of Rehabilitation Medicine
issn 1650-1977
1651-2081
publishDate 2018-07-01
description Objective: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic cerebral palsy, but its added value preceding comprehensive rehabilitation for motor impairments, gait, and goal attainment has not been studied. Design: A comparative multi-centre trial, in which two groups underwent comprehensive rehabilitation (i.e. high-intensive functional physiotherapy, and indicated casting/orthoses). One group received intramuscular BoNT-A prior to rehabilitation, and the other group did not receive BoNT-A. Subjects/patients: Children with spastic cerebral palsy, Gross Motor Function Classification System (GMFCS) levels I–III, age range 4–12 years, indicated for BoNT-A treatment regarding mobility problems. Methods: Sixty-five children participated (37 boys), mean age 7.3 years (standard deviation (SD) 2.3, range 4–12 years), equally distributed across GMFCS levels. Forty-one children received BoNT-A+ comprehensive rehabilitation and 24 received comprehensive rehabilitation only. Functional leg muscle strength, passive range of motion, angle of catch, cerebral palsy-related pain, walking speed, kinematic gait parameters, goal attainment, and proxy-reported general functioning were assessed at baseline, primary end-point (12 weeks) and 24-week follow-up. Statistical analyses were performed with linear mixed models. Results: At the primary end-point there were no statistically significant differences in treatment effects between the groups, except for the angle-of-catch of the rectus femoris, which was in favour of comprehensive rehabilitation without BoNT-A (12° difference, 95% confidence interval (95% CI) 2:23, p = 0.025). Results at follow-up were similar. Conclusion: At the group level, treating with BoNT-A prior to comprehensive rehabilitation did not add to the clinical effectiveness of rehabilitation. Thus, BoNT-A prescription and use should be critically reconsidered in this cerebral palsy age- and GMFCS-subgroup.
topic spasticcerebralpalsy
botulinumtoxin
functionalphysiotherapy
casting
orthoses
impairments
goalattainment
paediatricrehabilitation
url https://www.medicaljournals.se/jrm/content/html/10.2340/16501977-2369
work_keys_str_mv AT fabienneschasfoort intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy
AT robertpangalila intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy
AT emielmsneekes intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy
AT corienecatsman intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy
AT julesbecher intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy
AT herwinhoremans intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy
AT henkjstam intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy
AT annetjdallmeijer intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy
AT johannesbjbussmann intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy
_version_ 1725414933232877568